AU2020206593B2 - Transferrin receptor-binding molecules, conjugates thereof and their uses - Google Patents

Transferrin receptor-binding molecules, conjugates thereof and their uses

Info

Publication number
AU2020206593B2
AU2020206593B2 AU2020206593A AU2020206593A AU2020206593B2 AU 2020206593 B2 AU2020206593 B2 AU 2020206593B2 AU 2020206593 A AU2020206593 A AU 2020206593A AU 2020206593 A AU2020206593 A AU 2020206593A AU 2020206593 B2 AU2020206593 B2 AU 2020206593B2
Authority
AU
Australia
Prior art keywords
vhh
htfr
mtfr
egfp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020206593A
Other languages
English (en)
Other versions
AU2020206593A1 (en
Inventor
Romy COHEN
Marion David
Michel Khrestchatisky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Centre National de la Recherche Scientifique
Vect Horus
Original Assignee
Aix-Marseille Université
Centre National de la Recherche Scientifique
Vect Horus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix-Marseille Université, Centre National de la Recherche Scientifique, Vect Horus filed Critical Aix-Marseille Université
Publication of AU2020206593A1 publication Critical patent/AU2020206593A1/en
Application granted granted Critical
Publication of AU2020206593B2 publication Critical patent/AU2020206593B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2020206593A 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses Active AU2020206593B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305031 2019-01-09
EP19305031.7 2019-01-09
PCT/EP2020/050318 WO2020144233A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Publications (2)

Publication Number Publication Date
AU2020206593A1 AU2020206593A1 (en) 2021-07-15
AU2020206593B2 true AU2020206593B2 (en) 2026-02-05

Family

ID=65236972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020206593A Active AU2020206593B2 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Country Status (9)

Country Link
US (1) US12152317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908608A1 (cg-RX-API-DMAC7.html)
JP (1) JP7599425B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474369B (cg-RX-API-DMAC7.html)
AU (1) AU2020206593B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013559A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124790A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020144233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7652807B2 (ja) * 2020-06-24 2025-03-27 サプリーム テクノロジーズ,ベー.フェー. 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
CA3202539A1 (en) * 2020-12-02 2022-06-09 University Health Network Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
MX2023015520A (es) * 2021-07-01 2024-01-22 Denali Therapeutics Inc Conjugados de oligonucleotidos dirigidos al receptor de transferrina.
TW202330591A (zh) * 2021-11-19 2023-08-01 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
JP7889887B2 (ja) * 2021-12-02 2026-07-14 リンノ ファーマシューティカルズ インコーポレイテッド トランスフェリン結合抗体及びその使用
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
EP4504950A1 (en) 2022-04-01 2025-02-12 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
US20260116990A1 (en) 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
EP4622668A1 (en) 2022-11-23 2025-10-01 Key2Brain AB Vhh antibodies and uses thereof
KR20250114322A (ko) * 2022-12-02 2025-07-29 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-tfr1 항체 및 이의 용도
TW202436352A (zh) * 2023-02-07 2024-09-16 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
CN116179607A (zh) * 2023-03-27 2023-05-30 迦进生物医药(上海)有限公司 一种human TfR2高表达的稳转细胞株及其构建方法和应用
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
JP2026519919A (ja) 2023-04-03 2026-06-19 ブイアイビー ブイゼットダブリュ 血液脳関門通過抗体
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN121969643A (zh) 2023-06-22 2026-05-01 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗神经系统疾病的用途
EP4480964A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
WO2024261332A2 (en) 2023-06-22 2024-12-26 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
AU2024329222A1 (en) 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025194170A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
WO2025207959A1 (en) * 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202602933A (zh) * 2024-03-28 2026-01-16 美商健臻公司 與轉鐵蛋白受體1的特異性表位結合的多肽
WO2025226642A1 (en) 2024-04-25 2025-10-30 Eli Lilly And Company Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same
WO2026142988A1 (en) * 2024-12-24 2026-07-02 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization of c-c chemokine receptor 6

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031424A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
WO2014089209A2 (en) 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
EA035517B1 (ru) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031424A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
CN113474369B (zh) 2024-09-03
EA202191893A1 (ru) 2021-12-02
BR112021013559A2 (pt) 2021-09-21
WO2020144233A1 (en) 2020-07-16
JP2022518392A (ja) 2022-03-15
US20220090050A1 (en) 2022-03-24
EP3908608A1 (en) 2021-11-17
JP7599425B2 (ja) 2024-12-13
AU2020206593A1 (en) 2021-07-15
US12152317B2 (en) 2024-11-26
CA3124790A1 (en) 2020-07-16
CN113474369A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
US12152317B2 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
US10233252B2 (en) pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
US20230414780A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
CA3246387A1 (en) Lipid-based nanoparticles for targeted gene delivery to the brain
JP2017512464A (ja) インスリン様成長因子1受容体特異的抗体及びそれらの使用
JP2017514456A (ja) インスリン様成長因子1受容体特異的抗体及びそれらの使用
AU2017293450A1 (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
US20260062480A1 (en) Human blood-brain barrier targeting antibodies
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
JP7239987B2 (ja) 薬物送達のための抗体融合タンパク質
US20240174755A1 (en) Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
EA048741B1 (ru) Молекулы, связывающие рецептор трансферрина, их конъюгаты, и их применение
AU2024313677A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
CA3270656A1 (en) RAGE RECEPTOR-BINDING MOLECULES, THEIR CONJUGATES AND THEIR USES TO DETECT, PREVENT OR TREAT LUNG DISEASES
WO2020132301A1 (en) Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
CN121794291A (zh) 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)